Stocktoria
GRI Bio, Inc. GRI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-10
GRI Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| R&D expense | $6.8M | $3.8M | $3.2M | $242,000 | $5.2M |
| Operating income | -$12.0M | -$8.2M | -$11.4M | -$2.2M | -$9.3M |
| Income tax | $3,000 | $2,000 | — | — | — |
| Net income | -$12.0M | -$8.2M | -$13.0M | -$3.2M | -$9.3M |
| EPS (diluted) | $-121.80 | $-1545.55 | $-5018.09 | $-24.95 | $-1.42 |
| Operating cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Cash & equivalents | $8.2M | $5.0M | $1.8M | $9,000 | $3.7M |
| Total assets | $8.7M | $5.7M | $3.0M | $383,000 | $8.3M |
| Total liabilities | $2.7M | $1.7M | $2.7M | $2.0M | $2.5M |
| Shareholders' equity | $6.0M | $4.0M | $259,000 | -$1.6M | -$4.8M |
Source: SEC EDGAR filings · CIK 0001824293 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.